Google

Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Solstice facilitates shared solar energy solutions, aggregating consumer demand and connecting households with community solar projects. Founded in 2016, it aims to increase access to affordable renewable energy regardless of income or credit score.

If a technical career is what you seek, Benjamin Franklin Institute of Technology (BFIT) provides you with the education you need to pursue your professional goals. For over a century, BFIT has been one of Boston’s top career colleges. The institute has helped students reach their potential through technical education programs in the following types of fields: * Automotive Technology * Computer Technologies * Electronics Engineering Technology * Mechanical Engineering Technology * Medical Electronics Engineering Technology * Ophthalmic Assisting The Academic Success Center at BFIT ensures that students are given the resources and tools they need to excel in their academics and training. Some of the services offered through the center include: academic advising, special accommodations, tutoring, and more. College life at BFIT is filled with exciting experiences. From dorm life and council leadership to community service and intramural sports, the school encourages students to get involved in extracurricular activities. Applicants who are interested in admissions to the school must submit Accuplacer test results, an application, recommendation letters, and official transcripts for review. The school will waive its enrollment fee for any admissions applications submitted online. Merit and need-based financial aid exists in many forms at BFIT for those who qualify and are looking for tuition assistance.

Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on cancer therapeutics. It operates a laboratory dedicated to studying cancer-driving pathways and developing treatments that target and over-activate specific cancer-linked cell signaling, ultimately leading to the death of tumor cells.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Founded in 2017, Superplastic is a Vermont-based company that creates character-based products and entertainment. It designs limited edition art toys, apparel, games, and animation, collaborating with renowned artists to bring unique characters to life.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Phiar Technologies, a Boston-based company established in 2017, specializes in developing artificial intelligence solutions for vehicles. Its core product is an ultra-lightweight spatial AI engine that enables vehicles to perceive their surroundings in real-time using just a single camera and commodity mobile-grade processors. Phiar's initial focus is powering its Intelligent AR Navigation Platform, which provides drivers with safe and intuitive routing directions without requiring them to look away from the road.

Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

Founded in 2018, Merlin Labs is based in Boston, Massachusetts. It specializes in developing autonomous flight technology for fixed-wing aircraft, using artificial intelligence and machine learning to enable goods transportation without human pilots.

SingleStore is a data technology company that provides a distributed SQL database platform designed for real-time transactions and analytics. Its offerings include SingleStore DB, a distributed SQL database that can run on bare metal, in the cloud, or in hybrid deployments for operational analytics, and SingleStore Managed Service, a cloud database-as-a-service that provides analytics across a cloud of choice. The platform combines transactional and analytical processing in a single engine, supports real-time querying, multi-model data, and scalable ingestion, and aims to modernize data platforms, secure workloads, and support customer analytics across industries such as financial services, media and communications, energy and utilities, government, retail, and technology. Headquartered in San Francisco with additional offices, the company serves global enterprises by enabling real-time insights from data.

FYTO, Inc. is a company based in Cambridge, Massachusetts, founded in 2019, that specializes in the development of plant-based feed production systems. The firm focuses on creating nutrient-dense crops and innovative cultivation and harvesting systems designed to enhance agricultural quality and consistency. FYTO's offerings include a variety of agricultural products such as animal feed, fodder, plant-based proteins, nutritional supplements, and bio-fertilizers. By employing climate-friendly methodologies, the company aims to improve both the economic and environmental sustainability of agriculture, providing personalized solutions to farmers worldwide that promote ultra-high yields while minimizing resource requirements.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

RightHand Robotics, Inc. is a manufacturer of robotic order-picking systems that streamline supply chain logistics for various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company specializes in robotic solutions that automatically grasp a wide variety of items from bins and cases. Its flagship products include the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor designed to enhance the robots' ability to handle items gently and correct errors. RightHand Robotics focuses on providing end-to-end solutions that simplify integration and adaptation to diverse customer workflows, ultimately reducing the costs associated with order fulfillment across sectors such as electronics, apparel, grocery, and pharmaceuticals.

Scandit AG is a technology company specializing in barcode scanning software solutions and mobile computer vision. Founded in 2009 and headquartered in Zurich, Switzerland, with additional offices in the United States and Europe, Scandit develops applications that enable high-performance scanning on various smart devices, including smartphones, tablets, and wearables. Its offerings include the Barcode Scanner SDK, which transforms devices into enterprise-grade scanning tools, and the MatrixScan feature that enhances recognition processes for retail and logistics. Scandit's solutions are utilized across multiple industries, such as retail, healthcare, and manufacturing, to support applications like mobile shopping, inventory management, and asset tracking. The company's technology also incorporates augmented reality capabilities, providing real-time information overlays to improve user experience. Scandit aims to enhance operational efficiency and customer satisfaction for organizations, serving a diverse clientele that includes well-known brands.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

Founded in 2017, mabl provides an intelligent test automation platform that integrates seamlessly into CI/CD pipelines. It enables software teams to create reliable, auto-healing tests, enhancing application quality and speeding up delivery.

Founded in 2017, Superplastic is a Vermont-based company that creates character-based products and entertainment. It designs limited edition art toys, apparel, games, and animation, collaborating with renowned artists to bring unique characters to life.

RightHand Robotics, Inc. is a manufacturer of robotic order-picking systems that streamline supply chain logistics for various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company specializes in robotic solutions that automatically grasp a wide variety of items from bins and cases. Its flagship products include the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor designed to enhance the robots' ability to handle items gently and correct errors. RightHand Robotics focuses on providing end-to-end solutions that simplify integration and adaptation to diverse customer workflows, ultimately reducing the costs associated with order fulfillment across sectors such as electronics, apparel, grocery, and pharmaceuticals.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

SingleStore is a data technology company that provides a distributed SQL database platform designed for real-time transactions and analytics. Its offerings include SingleStore DB, a distributed SQL database that can run on bare metal, in the cloud, or in hybrid deployments for operational analytics, and SingleStore Managed Service, a cloud database-as-a-service that provides analytics across a cloud of choice. The platform combines transactional and analytical processing in a single engine, supports real-time querying, multi-model data, and scalable ingestion, and aims to modernize data platforms, secure workloads, and support customer analytics across industries such as financial services, media and communications, energy and utilities, government, retail, and technology. Headquartered in San Francisco with additional offices, the company serves global enterprises by enabling real-time insights from data.

Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.

Ribon Therapeutics, Inc. is a biotechnology company founded in 2015 and headquartered in Lexington, Massachusetts. The company focuses on developing novel therapeutics that target monoPARP proteins, which are critical regulators of cancer cell survival mechanisms. By leveraging insights from its scientific founders, Ribon is establishing a proprietary drug discovery platform aimed at investigating the molecular actions and biological functions of a specific subset of the PARP protein family. This platform enables Ribon to create a pipeline of innovative small molecule inhibitors designed to disrupt the fundamental survival capabilities of cancer cells under stress. In addition to cancer treatment, the company's research may have implications for addressing other diseases. Ribon is supported by notable life science investors, which enhances its capacity to advance its therapeutic developments.

Founded in 2018, Merlin Labs is based in Boston, Massachusetts. It specializes in developing autonomous flight technology for fixed-wing aircraft, using artificial intelligence and machine learning to enable goods transportation without human pilots.

Founded in 2018, Dyno Therapeutics specializes in developing adeno-associated virus (AAV) vectors for in vivo gene therapy delivery. The company's proprietary platform combines DNA synthesis of AAV capsids with sequencing and machine learning to create novel vectors tailored for safe, efficient, and targeted therapeutic solutions.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Treeline Biosciences is a biotechnology company focused on developing precision medicines for cancer and other serious diseases. Founded in 2021 and based in Stamford, Connecticut, the company uses a platform that integrates pathophysiology, genomics, and pattern recognition to identify therapeutic approaches that address unmet patient needs.

Founded in 2019, Tend is a modern dental practice committed to redefining oral healthcare. With over 650 team members across 25 locations in six major U.S. cities, Tend offers personalized, hassle-free dental services in inviting spaces, focusing on patient happiness and comfort.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

SingleStore is a data technology company that provides a distributed SQL database platform designed for real-time transactions and analytics. Its offerings include SingleStore DB, a distributed SQL database that can run on bare metal, in the cloud, or in hybrid deployments for operational analytics, and SingleStore Managed Service, a cloud database-as-a-service that provides analytics across a cloud of choice. The platform combines transactional and analytical processing in a single engine, supports real-time querying, multi-model data, and scalable ingestion, and aims to modernize data platforms, secure workloads, and support customer analytics across industries such as financial services, media and communications, energy and utilities, government, retail, and technology. Headquartered in San Francisco with additional offices, the company serves global enterprises by enabling real-time insights from data.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Founded in 2017, Superplastic is a Vermont-based company that creates character-based products and entertainment. It designs limited edition art toys, apparel, games, and animation, collaborating with renowned artists to bring unique characters to life.

Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, is an autonomous coding solution that streamlines revenue cycle management. Nym reduces denials and operational expenses by directly billing and accurately assigning medical charge codes from patient charts, improving payment cycles and audit-readiness. It identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. With a research and development center in Tel Aviv-Yafo, Israel, Nym enables healthcare providers to enhance coding quality, lower costs, and focus more on patient care.

Founded in 2019, Tend is a modern dental practice committed to redefining oral healthcare. With over 650 team members across 25 locations in six major U.S. cities, Tend offers personalized, hassle-free dental services in inviting spaces, focusing on patient happiness and comfort.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

Scandit AG is a technology company specializing in barcode scanning software solutions and mobile computer vision. Founded in 2009 and headquartered in Zurich, Switzerland, with additional offices in the United States and Europe, Scandit develops applications that enable high-performance scanning on various smart devices, including smartphones, tablets, and wearables. Its offerings include the Barcode Scanner SDK, which transforms devices into enterprise-grade scanning tools, and the MatrixScan feature that enhances recognition processes for retail and logistics. Scandit's solutions are utilized across multiple industries, such as retail, healthcare, and manufacturing, to support applications like mobile shopping, inventory management, and asset tracking. The company's technology also incorporates augmented reality capabilities, providing real-time information overlays to improve user experience. Scandit aims to enhance operational efficiency and customer satisfaction for organizations, serving a diverse clientele that includes well-known brands.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Arrakis Therapeutics, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, that specializes in drug discovery focused on ribonucleic acid (RNA) targets. Established in 2015, the company utilizes a proprietary platform that combines advanced RNA bioinformatics, structural tools, and chemical libraries to identify new RNA targets and develop RNA-targeted small molecules (rSMs). This innovative approach aims to address various diseases, including cancer, neurological disorders, and rare genetic conditions. Arrakis also offers SHAPEware, a software tool designed to analyze and predict RNA secondary structures and potential ligand-binding sites, further enhancing its drug development capabilities. Through its comprehensive pipeline, Arrakis Therapeutics seeks to improve treatment options and outcomes for patients across multiple therapeutic areas.

Lola Travel Company, Inc. specializes in corporate travel management through its AI-driven platform, Lola.com. Established in 2015 and headquartered in Boston, Massachusetts, the company simplifies the travel booking process for businesses by offering an intuitive tool for flight and hotel reservations. Lola.com allows users to manage itineraries via a mobile application, providing individual travel profiles, digital travel receipts, and budget tracking services. The platform also supports employee-friendly travel policies, efficient spend reporting for managers, and features that enable team destination sharing and loyalty point accumulation. With 24/7 agent assistance and capabilities for executive assistants to book travel on behalf of others, Lola.com caters to the needs of both employers and business travelers, streamlining the overall travel experience.

Beam Therapeutics is a biotechnology company developing precision genetic medicines using its proprietary base editing technology. Its focus includes therapies for hematological and genetic diseases, with ongoing programs targeting sickle cell disease, alpha-1 antitrypsin deficiency, and other serious conditions.

Relay Therapeutics, Inc. is a clinical-stage precision medicine company based in Cambridge, Massachusetts, focused on transforming the drug discovery process. The company employs a novel allosteric drug-discovery platform, known as Dynamo, which integrates advanced computational techniques with experimental methods to study protein motion and interactions. This innovative approach enables the identification and development of therapies targeting complex diseases, particularly in oncology. Relay Therapeutics is advancing a pipeline of product candidates, including RLY-1971, a small molecule inhibitor targeting SHP2, RLY-4008, a selective inhibitor of FGFR2 for advanced solid tumors, and RLY-PI3K1047, aimed at mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, the company aims to deliver life-changing therapies to patients by addressing previously intractable targets in precision oncology and genetic diseases.

RightHand Robotics, Inc. is a manufacturer of robotic order-picking systems that streamline supply chain logistics for various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company specializes in robotic solutions that automatically grasp a wide variety of items from bins and cases. Its flagship products include the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor designed to enhance the robots' ability to handle items gently and correct errors. RightHand Robotics focuses on providing end-to-end solutions that simplify integration and adaptation to diverse customer workflows, ultimately reducing the costs associated with order fulfillment across sectors such as electronics, apparel, grocery, and pharmaceuticals.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Founded in 2017, mabl provides an intelligent test automation platform that integrates seamlessly into CI/CD pipelines. It enables software teams to create reliable, auto-healing tests, enhancing application quality and speeding up delivery.

Yesware, Inc. is a technology company that specializes in developing a prescriptive sales platform tailored for startups and sales professionals globally. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware offers an all-in-one toolkit for sales within email platforms such as Outlook and Gmail. This toolkit enables sales professionals to track emails, schedule communications, set reminders, and place calls directly from their inboxes. Yesware's platform is designed to enhance sales productivity by providing advanced analytics, customizable email templates, and integration with customer relationship management systems. It supports both small businesses and large enterprises, helping organizations streamline their sales processes and improve customer engagement. Yesware is trusted by companies like Yelp, Twitter, and Monday.com, and has been installed over 1.2 million times, demonstrating its widespread adoption in the sales industry.

Scandit AG is a technology company specializing in barcode scanning software solutions and mobile computer vision. Founded in 2009 and headquartered in Zurich, Switzerland, with additional offices in the United States and Europe, Scandit develops applications that enable high-performance scanning on various smart devices, including smartphones, tablets, and wearables. Its offerings include the Barcode Scanner SDK, which transforms devices into enterprise-grade scanning tools, and the MatrixScan feature that enhances recognition processes for retail and logistics. Scandit's solutions are utilized across multiple industries, such as retail, healthcare, and manufacturing, to support applications like mobile shopping, inventory management, and asset tracking. The company's technology also incorporates augmented reality capabilities, providing real-time information overlays to improve user experience. Scandit aims to enhance operational efficiency and customer satisfaction for organizations, serving a diverse clientele that includes well-known brands.

Tamr is an enterprise data unification company based in Cambridge, Massachusetts. It builds a platform that uses machine learning and human insight to connect and enrich disparate data sources at scale. The solution supports data preparation, mastering, and integration for industries such as financial services, life sciences, government, oil and gas, manufacturing, consumer packaged goods, telecommunications, and media. It offers applications for procurement analytics, clinical data conversion, media analytics, and customer data integration. The platform helps organizations derive actionable insights and improve decision-making. Founded in 2013 by database experts, it has deployed in production at information services providers, pharmaceutical firms, and retailers.

Openbay is a marketplace and software provider for the automotive care industry. It operates an online platform that helps vehicle owners find, compare quotes for, book, and pay for automotive repair and maintenance services from a network of car dealerships, national chains, independent shops, and mobile mechanics. The company also offers SaaS software that enables providers to manage listings, respond to quotes, and process bookings. Founded in 2011 and based in Cambridge, Massachusetts, Openbay serves to create a transparent, convenient experience for customers and service providers.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

SingleStore is a data technology company that provides a distributed SQL database platform designed for real-time transactions and analytics. Its offerings include SingleStore DB, a distributed SQL database that can run on bare metal, in the cloud, or in hybrid deployments for operational analytics, and SingleStore Managed Service, a cloud database-as-a-service that provides analytics across a cloud of choice. The platform combines transactional and analytical processing in a single engine, supports real-time querying, multi-model data, and scalable ingestion, and aims to modernize data platforms, secure workloads, and support customer analytics across industries such as financial services, media and communications, energy and utilities, government, retail, and technology. Headquartered in San Francisco with additional offices, the company serves global enterprises by enabling real-time insights from data.

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.

Relay Therapeutics, Inc. is a clinical-stage precision medicine company based in Cambridge, Massachusetts, focused on transforming the drug discovery process. The company employs a novel allosteric drug-discovery platform, known as Dynamo, which integrates advanced computational techniques with experimental methods to study protein motion and interactions. This innovative approach enables the identification and development of therapies targeting complex diseases, particularly in oncology. Relay Therapeutics is advancing a pipeline of product candidates, including RLY-1971, a small molecule inhibitor targeting SHP2, RLY-4008, a selective inhibitor of FGFR2 for advanced solid tumors, and RLY-PI3K1047, aimed at mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, the company aims to deliver life-changing therapies to patients by addressing previously intractable targets in precision oncology and genetic diseases.

Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

Rodin Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through epigenetic modulation. Founded in 2013, the company leverages insights into key epigenetic regulators of central nervous system (CNS) function to create innovative treatments. Rodin's approach involves harnessing the power of epigenetic regulation, particularly through the modulation of HDAC complexes, to restore synaptic function and enhance neuronal health in patients suffering from degenerative brain diseases. The company is supported by a team experienced in CNS drug development and has access to advanced structural biology capabilities. Rodin Therapeutics operates as a subsidiary of Alkermes Inc.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Toast is a cloud-based point-of-sale and restaurant-management platform for the food service and hospitality industry. It offers an end-to-end system that combines front-of-house and back-of-house functionality, including tableside ordering, online ordering, delivery tracking, labor management, and real-time reporting. The platform serves a broad range of establishments such as restaurants, bakeries, cafes, bars, nightclubs, and pizzerias, with a focus on mid-market operators primarily in the United States. Toast generates revenue from the sale of restaurant-grade hardware and recurring subscriptions and services tied to transaction volume. As of fiscal 2024, it served approximately 134,000 restaurant locations, and its typical customer generates slightly more than $1 million in annual revenue. The company is headquartered in Boston and maintains additional offices in Portland, Oregon; Omaha, Nebraska; and Dublin, Ireland.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

Founded in 2014, Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics to treat solid tumors and hematological malignancies. Its pipeline includes CTX-471, an agonistic antibody of CD137 for immune cell activation, currently in Phase I trials; CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, in IND-enabling studies; and CTX-009, a bispecific antibody inhibiting DLL4 and VEGF-A signaling, completed Phase I and is in Phase Ib combination with chemotherapy.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on advancing stem cell transplantation and related therapies. Founded in 2015, the company aims to enhance the patient experience in transplant medicine by developing innovative treatments that make stem cell transplants safer and more accessible. Its pipeline includes several key candidates, such as C100, C200, and C300 targeted antibody-drug conjugates designed for transplant conditioning; MGTA-145, a stem cell mobilization product; and MGTA-456, an allogeneic stem cell therapy. Additionally, Magenta is exploring E478, a small molecule aimed at expanding gene-modified stem cells, and G100, an antibody-drug conjugate to mitigate acute graft-versus-host disease. The company has established research collaborations with other biotechnology firms to further investigate the potential of its therapies in treating blood cancers, genetic disorders, and autoimmune diseases, ultimately striving to transform stem cell transplantation from a last-resort option into a more viable and effective treatment for patients.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

Desktop Metal is a global developer and manufacturer of additive manufacturing technologies, materials, and software for industrial production. The company offers a range of metal 3D printing systems, including the Production System for high-volume manufacturing, the Shop System for machine shops, the Studio System for office environments, and the Fiber printer for desktop use. It supplies materials and software that support metal, polymer, sand, and ceramic applications, enabling on-demand, digital mass production with improved speed, cost efficiency, and part quality. Desktop Metal serves automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development customers and operates worldwide from headquarters in Burlington, Massachusetts.

Lola Travel Company, Inc. specializes in corporate travel management through its AI-driven platform, Lola.com. Established in 2015 and headquartered in Boston, Massachusetts, the company simplifies the travel booking process for businesses by offering an intuitive tool for flight and hotel reservations. Lola.com allows users to manage itineraries via a mobile application, providing individual travel profiles, digital travel receipts, and budget tracking services. The platform also supports employee-friendly travel policies, efficient spend reporting for managers, and features that enable team destination sharing and loyalty point accumulation. With 24/7 agent assistance and capabilities for executive assistants to book travel on behalf of others, Lola.com caters to the needs of both employers and business travelers, streamlining the overall travel experience.

Qwiklabs Inc. is a company that specializes in providing virtual lab environments for software training, enabling developers and IT professionals to gain hands-on experience with cloud technologies, particularly those associated with AWS. Founded in 2012 and headquartered in Carlisle, Massachusetts, Qwiklabs offers a platform that allows clients to create, manage, and operate labs for various applications, including security, big data, and serverless web apps. The platform features a wide array of self-paced labs and AWS-authorized instructor-led training courses, ensuring learners can access real-world scenarios in actual AWS environments. Qwiklabs also provides a flexible pricing model, allowing users to access specific labs or opt for an all-inclusive subscription. Additionally, learners can earn badges and complete quests to enhance their knowledge and credentials in key areas such as AWS Certification Exam preparation and advanced operations. As of November 2016, Qwiklabs operates as a subsidiary of Alphabet Inc.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

Plexxi Inc. is a provider of converged application-defined network infrastructure designed for software-defined data centers and public/private clouds. The company develops networking solutions that enhance application performance and facilitate the building of private, public, and hybrid cloud networks. Its offerings include a comprehensive suite of tools, ranging from hardware to management and application integrations, which allow cloud builders to operate with greater efficiency and responsiveness. Founded in 2010 and based in Nashua, New Hampshire, Plexxi operates as a subsidiary of Hewlett Packard Enterprise Company since June 2018. The firm has established a strategic partnership with Decision Lab, LLC, further enhancing its capabilities in delivering optimized networking solutions.

Toast is a cloud-based point-of-sale and restaurant-management platform for the food service and hospitality industry. It offers an end-to-end system that combines front-of-house and back-of-house functionality, including tableside ordering, online ordering, delivery tracking, labor management, and real-time reporting. The platform serves a broad range of establishments such as restaurants, bakeries, cafes, bars, nightclubs, and pizzerias, with a focus on mid-market operators primarily in the United States. Toast generates revenue from the sale of restaurant-grade hardware and recurring subscriptions and services tied to transaction volume. As of fiscal 2024, it served approximately 134,000 restaurant locations, and its typical customer generates slightly more than $1 million in annual revenue. The company is headquartered in Boston and maintains additional offices in Portland, Oregon; Omaha, Nebraska; and Dublin, Ireland.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Panorama Education, Inc. is a data analytics company based in Boston, Massachusetts, that focuses on K-12 education. Founded in 2012, the company provides a software-as-a-service (SaaS) platform that enables school districts, charter networks, and state governments to conduct comprehensive surveys of students, parents, teachers, and staff. Through its research-based surveys, Panorama collects valuable feedback on various aspects of the educational environment, including teacher performance and school climate. The platform generates detailed reports that allow educators and administrators to analyze results across different demographics. Additionally, Panorama offers implementation consultation, technical assistance, and training to enhance the effectiveness of its services. By leveraging stakeholder feedback, the company aims to support professional development and improve student outcomes in schools.

Tamr is an enterprise data unification company based in Cambridge, Massachusetts. It builds a platform that uses machine learning and human insight to connect and enrich disparate data sources at scale. The solution supports data preparation, mastering, and integration for industries such as financial services, life sciences, government, oil and gas, manufacturing, consumer packaged goods, telecommunications, and media. It offers applications for procurement analytics, clinical data conversion, media analytics, and customer data integration. The platform helps organizations derive actionable insights and improve decision-making. Founded in 2013 by database experts, it has deployed in production at information services providers, pharmaceutical firms, and retailers.

Yesware, Inc. is a technology company that specializes in developing a prescriptive sales platform tailored for startups and sales professionals globally. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware offers an all-in-one toolkit for sales within email platforms such as Outlook and Gmail. This toolkit enables sales professionals to track emails, schedule communications, set reminders, and place calls directly from their inboxes. Yesware's platform is designed to enhance sales productivity by providing advanced analytics, customizable email templates, and integration with customer relationship management systems. It supports both small businesses and large enterprises, helping organizations streamline their sales processes and improve customer engagement. Yesware is trusted by companies like Yelp, Twitter, and Monday.com, and has been installed over 1.2 million times, demonstrating its widespread adoption in the sales industry.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

Recorded Future is a threat intelligence company that provides real-time, multi-source insights to help organizations anticipate and defend against cyber threats. Its Intelligence Cloud collects and analyzes data from the open web, dark web, and technical sources to deliver contextualized information on adversaries, infrastructure, and targets, enabling security teams to detect indicators of compromise, monitor brand and assets, and respond faster. The platform supports threat intelligence teams and security operations centers with automated alerts, dashboards, and on-demand reports, and offers services such as analyst-backed research and goal-driven intelligence. It also provides dark web monitoring, executive protection capabilities, and integrations with security tools, including a Palo Alto Networks lookup app for log searches. Recorded Future maintains headquarters in Somerville, Massachusetts, with offices in McLean, Virginia, and Gothenburg, Sweden. Founded in 2009, the company uses machine learning to deliver real-time, contextualized intelligence and reduce cybersecurity risk.

Adelphic, Inc. is a company that specializes in developing a mobile and cross-channel programmatic advertising platform aimed at connecting brands with audiences. Founded in 2011 and based in Waltham, Massachusetts, Adelphic offers a self-service software solution that allows non-technical users to manage advertising campaigns effectively. Its platform is designed to facilitate meaningful engagements with consumers across various devices and formats, utilizing real-time bidding capabilities to ensure global reach. Key features of the platform include a campaign management portal, Audience Cube for data segmentation and insights, and predictive performance engine solutions. Adelphic primarily serves agencies, brands, and large media buyers, enabling them to overcome user identification limitations in digital advertising by providing rich, detailed profiles of consumers. As of early 2017, Adelphic operates as a subsidiary of Viant Technology Inc.

Tamr is an enterprise data unification company based in Cambridge, Massachusetts. It builds a platform that uses machine learning and human insight to connect and enrich disparate data sources at scale. The solution supports data preparation, mastering, and integration for industries such as financial services, life sciences, government, oil and gas, manufacturing, consumer packaged goods, telecommunications, and media. It offers applications for procurement analytics, clinical data conversion, media analytics, and customer data integration. The platform helps organizations derive actionable insights and improve decision-making. Founded in 2013 by database experts, it has deployed in production at information services providers, pharmaceutical firms, and retailers.